## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 2.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($502.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Ulta Beauty tops Wall Street expectations for third quarter**
- Source: Mass Market Retailers | 20251204T234447 | Bullish | Relevance: 100%
- Ulta Beauty Inc. exceeded Wall Street's revenue and earnings expectations for its third quarter, prompting the beauty retailer to raise its full-year profit and sales outlook. The company's "Ulta Beauty Unleashed" strategy, featuring new assortments, improved experiences, and bold marketing, drove strong sales and market share gains across all categories and channels, particularly e-commerce. Ulta also expanded its physical footprint and launched its first international stores in Mexico, alongside a third-party marketplace.

**2. The one thing people are still buying? Beauty products, and Ulta just proved it.**
- Source: MarketWatch | 20251204T231022 | Bullish | Relevance: 100%
- Ulta Beauty Inc. recently exceeded Wall Street expectations with its quarterly earnings and raised its sales outlook for the year, indicating that consumers are still willing to spend on beauty products despite cutting costs elsewhere. The company's "masstige" strategy, offering a mix of mass-produced and prestige items, is seen as a key factor in its success. Analysts note the beauty category remains healthy, benefiting from consumers seeking quality at value prices.

**3. The one thing people are still buying? Beauty products, and Ulta just proved it.**
- Source: MarketWatch | 20251204T230847 | Bullish | Relevance: 100%
- Ulta Beauty Inc. exceeded Wall Street earnings expectations and raised its sales outlook, indicating that consumers continue to prioritize spending on cosmetics and hair products despite cutting costs elsewhere. The company's "masstige" strategy, combining mass-produced and prestige offerings, is seen as a key driver for its success, catering to demand for premium quality at value prices. This strong performance highlights the resilience of the beauty category even in challenging economic times.

**4. Ulta Beauty Surpasses Q3 Expectations With $2.9B in Sales, Driven by Fragrance Boom and International Expansion**
- Source: WWD | 20251204T225022 | Bullish | Relevance: 100%
- Ulta Beauty reported strong Q3 2025 results, exceeding Wall Street expectations with $2.9 billion in sales, an increase of 12.9 percent. This growth was primarily fueled by robust fragrance and K-beauty sales, successful international expansion into Mexico and the Middle East, and the launch of its new marketplace. The company raised its full-year 2025 net sales forecast to $12.3 billion, demonstrating positive momentum from its "Ulta Beauty Unleashed Strategy."

**5. The one thing people are still buying? Beauty products, and Ulta just proved it.**
- Source: MarketWatch | 20251204T224322 | Bullish | Relevance: 100%
- Ulta Beauty Inc. (ULTA) raised its sales outlook and exceeded earnings expectations, demonstrating that consumers are prioritizing beauty products even while cutting back on other spending. Analysts attribute Ulta's success to its "masstige" strategy, offering a mix of mass-produced and prestige items to appeal to those seeking value and quality. This trend suggests the beauty category remains resilient against broader economic pressures.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-01 | JP Morgan | $606 | $600 | +1% |
| 2025-12-01 | Telsey Advisory | $610 | $610 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-01 | JP Morgan | main | Overweight |
| 2025-12-01 | Telsey Advisory | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- New product launch cycle could drive revenue acceleration.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.46 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 48%, ROA 15%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.2B |
| Beta | 0.87 |
| 52W Range | $309.01 - $616.34 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.46 |
| Forward P/E | 18.9 |
| Current P/E | 20.9 |
| YoY Growth | 10.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.6% to -1.1% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (3.49), confirming momentum. RSI neutral at 54. OFD pattern: -MUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.12% (CS: 42) | Neutral |
| RSI_14 | 53.8 | Neutral |
| MACD Histogram | 3.49 | Bullish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.151x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $533.95
- **Stop Loss:** $502.57 (5.9% risk)
- **Target:** $565.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $16,552.45
- **Portfolio %:** 16.55%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.7% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*